title: Efficacy of brinzolamide ophthalmic suspension 1% for treatment of a vitelliform macular lesion in a patient with desferrioxamine retinopathy.
abstract: A 46-year-old woman with a vitelliform macular lesion secondary to desferrioxamine retinal toxicity in the right eye was treated with brinzolamide 1% ophthalmic drops three times a day. A spectral-domain optical coherence tomography (SD-OCT) unit was used to monitor any changes in the macular lesion. Two months after starting the eye drops, the SD-OCT showed a notable improvement in the vitelliform macular lesion's thickness. Six months later, further improvement was noted in the macular lesion thickness on SD-OCT testing in the right eye. Best-corrected visual acuity was initially 1.00 logarithm of the minimum angle of resolution (20/200 on a Snellen acuity chart) in the right eye and 0.14 logarithm of the minimum angle of resolution (20/25(-2)) in the left eye. After 6 months of treatment, visual acuity was 0.92 (20/200(+1)) in the right eye and 0.08 (20/25(+1)) in the left eye. The use of brinzolamide 1% was associated with a marked reduction in a vitelliform macular lesion on SD-OCT testing secondary to desferrioxamine retinal toxicity.
authors.affiliation: Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, USA.
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Genead
authors.forename: Gerald A
authors.initials: GA
authors.lastname: Fishman
mesh_terms: D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use*; D003676:Deferoxamine / Q000009:adverse effects; D005260:Female; D006801:Humans; D008266:Macula Lutea / Q000187:drug effects; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D012164:Retinal Diseases / Q000139:chemically induced / Q000188:drug therapy*; D017262:Siderophores / Q000009:adverse effects; D013449:Sulfonamides / Q000627:therapeutic use*; D013843:Thiazines / Q000627:therapeutic use*; D041623:Tomography, Optical Coherence / Q000379:methods; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D009883:Ophthalmic Solutions; D017262:Siderophores; D013449:Sulfonamides; D013843:Thiazines; C111827:brinzolamide; D003676:Deferoxamine